EP PerMed JTC2025 Pre-announcement – Pharmacogenomic Strategies for Personalised Medicine (PGxPM2025)


Convocatoria "abierta"
Me interesa
Entidad convocante:
European Commission
Categoría:
Projectes de recerca
Ámbito:
Inicio:
Plazo interno:
Plazo real:
Cuantía:
Discretionary
Descripción:

The European Partnership for Personalised Medicine, EP PerMed (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), is a platform for joint programming of national and European regional research and innovation supporting activities putting into action "The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023)" , SRIA for PM (2023), through dedicated research, development and innovation funding.

EP PerMed funding organisations, listed below, have agreed to launch the joint transnational call 2025 (JTC2025), co-funded by the EU, to fund multinational innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe in this field. The JTC2025 will be conducted simultaneously by the participating funding organisations in their respective region/country and coordinated centrally by the Joint Call Secretariat (JCS), hosted by the German Aerospace Center e.V. - Project Management Agency, (DLR-PT), Germany.

The call will be implemented in two stages, i.e. a pre- and a full-proposal phase. The available budget for this call is 35 Mio. € (approx.).

Aims of the Call

The overall objectives of the JTC2025 will be to

  • Support research projects in human health on pharmacogenomic strategies for personalised medicine approaches that address one or more of the following aspects:
    • identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.
    • validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.
    • use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).
  • Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice.
  • Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
  • Establish participatory research, i.e. active representation of patients or citizens as part of research projects.

Research projects in all disease areas will be welcome.

Requisitos

General (Eligibility) Conditions for Application

Joint research proposals may be submitted by applicants belonging to the following categories (subject to regional/national funding regulations):

  1. Academia (research teams working in universities, other higher education institutions) or research institutes;
  2. Clinical/public health sector (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;
  3. Private for-profit (industry) partners, e.g. SME (small and medium-sized enterprises) and private non-profit partners, e.g. foundations, associations or non-governmental organisations.

More information about the eligibility criteria and rules regarding consortium composition will be available soon

Splicitud

In case of interest, please click on "m'interessa" and we will contact you.